VivoSeq
Other

Amputation

33

Pipeline Programs

17

Active Trials

15

Companies Involved

Amputation is a moderately active landscape with 33 programs across 15 companies. The most active players are Revance Therapeutics, Inc., AbbVie, TLC Biopharmaceuticals, Inc.. 9 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

30/100

Mech. Concentration

15/100

Completion Rate

63/100

Attrition Rate

18/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

95%

Small molecule

40 of 42 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody12%Cell therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.

Trial Status

50

clinical trials

Completed15 · 30%
Recruiting12 · 24%
Unknown status9 · 18%
Terminated8 · 16%
Not yet recruiting3 · 6%
Active, not recruiting2 · 4%
Other1 · 2%

Trial Activity

50 trials

Prosthetic Performance Enhancement Trial
Recruiting·UUniversity of Nevada, Las Vegas·Preclinical·NCT06419920·35 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)